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Purpose
MRI evaluation can be a helpful adjunct to clinical
assessment of disease states in adult RA but has not
been extensively investigated in children with JIA. MRI
is a sensitive examination available to detect active syno-
vial inflammation and can identify bone edema, known
to be an important predictor for future joint erosions.
By evaluating for such abnormalities, MRI could help
differentiate children with active JIA from those with
inactive disease (ID). The objectives were to determine
if MRI with IV gadolinium (gad) (i) correlates with the
clinical state of disease activity and (ii) can biologically
confirm the state of clinically ID in children with JIA
treated with early aggressive therapy.
Methods
TREAT was a 12 mo randomized, double blind, multi-
centered clinical trial in 85 participants aged 2 to 16 yrs
with polyarticular or extended oligoarticular JIA of ≤ 12
mos duration. Participants were randomized 1:1 into 1 of
2 aggressive treatment arms: Arm 1- MTX 0.5 mg/kg/wk
SQ (40 mg max), plus etanercept 0.8 mg/kg/wk (50 mg
max), plus prednisone 0.5 mg/kg/d (60 mg max) tapered
to 0 by 17 wks, or Arm 2 - MTX (same dose) plus etaner-
cept and prednisolone placebo. The primary outcome
was achievement of ID by 6 mos. At 4 mos participants
not achieving an ACR Pediatric 70 were treated with
open label Arm 1 meds. A subset of participants ≥ age 6
with knee synovitis underwent MRI with IV gad (0.1mg/
kg) of 1 affected knee at baseline and after 6 mos of ther-
apy. MRI pulse sequences included: single plane of fat-
saturated fluid sensitive, single plane of T1 fat-saturated
pre IV gad, 2 planes of T1 fat-saturated post IV gad,
single plane of 3D spoiled gradient, and a single plane of
Proton Density. Blinded MRIs were read independently
by 2 radiologists.
Results
11 participants were recruited into the MRI sub-study. At
baseline, physician examination was concordant with
MRI abnormalities of synovitis in 11 of 11 and effusion
in 10 of 11. Of these, 3 of 11 had enlarged lymph nodes
in the popliteal fossa, and 1 each had: prepatellar soft tis-
sue edema, a multiseptated baker’s cyst with partial rup-
ture, and bony edema; none had cartilage loss or
erosions. There were 10 6-mo follow-up MRIs of which 6
showed complete resolution of abnormalities, including
enlarged lymph nodes and prepatellar soft tissue edema.
Four of these 6 participants were in Arm 1 and 2 were in
Arm 2. The remaining 4 follow up MRIs (3 in Arm 1,
1 in Arm 2) showed improvements in the amount of
synovitis and effusion, but new bony edema in 2 of these.
At 6 mos, there was discordance between clinical exam
and MRI findings in 40% of participants: 2 had clinical
findings of knee swelling, but no abnormalities on MRI,
and 2 had a normal clinical exam but abnormal MRI
findings of synovitis and effusion. None of those with
abnormal MRIs at follow up had achieved clinical ID.
Conclusion
Joint damage/erosions were rare in this patient cohort.
MRI evaluation may be a helpful adjunct for documen-
tation of the clinical state of inactive disease in patients
with JIA and assist in the correct classification of disease
state.
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